Judiciary Committee
- Referred To
- Markup By
- Reported By
Introduced: Mar 24, 2025
Latest action date: Apr 10, 2025
Current stage
In committee
The most advanced recorded stage is committee consideration.
Introduced
Mar 24, 2025
Latest action
Apr 10, 2025
Recorded roll calls
0
Civixly topics
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Health
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Sep 12, 2026.
Newest action first. Action language comes from the official Congress.gov record.
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
0 comments
Loading comments...